Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTCN 213
Description: NMDA antagonist; selective for GluN2A over GluN2B containing receptors
Chemical Name: N-(Cyclohexylmethyl)-2-[(5-[(phenylmethyl)amino]-1,3,4-thiadiazol-2-yl}thio]acetamide
Purity: ≥99% (HPLC)
Biological Activity for TCN 213
TCN 213 is a NMDA receptor antagonist, selective for GluN1/GluN2A (formally NR1/NR2A) (pIC50 = 5.4) over GluN1/GluN2B (formally NR1/NR2B) containing receptors.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
Technical Data for TCN 213
| M. Wt | 376.54 |
| Formula | C18H24N4OS2 |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 556803-08-8 |
| PubChem ID | 2608149 |
| InChI Key | XBAZPYFIYYCZBO-UHFFFAOYSA-N |
| Smiles | O=C(NCC2CCCCC2)CSC1=NN=C(NCC3=CC=CC=C3)S1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for TCN 213
References for TCN 213
References are publications that support the biological activity of the product.
Bettini et al (2010) Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. J.Pharmacol.Exp.Ther. 335 644 PMID: 20810618
McKay et al (2012) Direct pharmacological monitoring of the developmental switch in NMDAR subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. Br.J.Pharmacol. 166 924 PMID: 22022974
View Related Products by Target
View Related Products by Product Action
Keywords: TCN 213, TCN 213 supplier, TCN213, selective, NMDA, receptor, antagonist, NR1/NR2A, NR2A-containing, NR2B, GluN1, GluN2A, GluN2B, Receptors, 4163, Tocris Bioscience
3 Citations for TCN 213
Citations are publications that use Tocris products. Selected citations for TCN 213 include:
Izumi and Zorumski (2015) Sensitivity of N-MthD.-aspartate receptor-mediated excitatory postsynaptic potentials and synaptic plasticity to TCN 201 and TCN 213 in rat hippocampal slices. Int J Mol Sci 352 267 PMID: 25413830
Prickett et al (2014) Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. J Invest Dermatol 134 2390 PMID: 24739903
McKay et al (2012) Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist. Br J Pharmacol 166 924 PMID: 22022974
Reviews for TCN 213
There are currently no reviews for this product. Be the first to review TCN 213 and earn rewards!
Have you used TCN 213?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.